Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

被引：0
作者：
Christopher T. Su
J. Christine Ye
机构：
[1] University of Michigan,Department of Internal Medicine
[2] University of Michigan,Rogel Cancer Center
来源：
Journal of Hematology & Oncology | / 14卷
关键词：
Multiple myeloma; Review; First in human trials; Chimeric antigen receptor; CAR-T; Bispecific antibody; T cell engager; Antibody–drug conjugate; Monoclonal antibody; Small molecule inhibitor; Targeted therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical approval with significant implications in extending patient survival and advancing closer to the goal of a cure, especially in areas of immunotherapy such as chimeric antigen receptor T cells, bispecific T cell engager antibodies, antibody drug conjugates, newer generations of monoclonal antibodies, and small molecule inhibitor and modulators. This review provides an update of current myeloma therapeutics in active preclinical and early clinical development and discusses the mechanism of action of several classes of novel therapeutics.
引用
收藏
相关论文
共 964 条
[1]  
Mikhael J(2019)Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline J Clin Oncol 37 1228-1263
[2]  
Ismaila N(2017)Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma J Clin Oncol 35 1312-1319
[3]  
Cheung MC(2020)Somatic genomic mosaicism in multiple myeloma Front Genet 11 388-221
[4]  
Costello C(2020)Genome chaos: creating new genomic information essential for cancer macroevolution Semin Cancer Biol 21 207-716
[5]  
Dhodapkar MV(2020)Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study Lancet Oncol 384 705-25
[6]  
Kumar S(2021)Idecabtagene vicleucel in relapsed and refractory multiple myeloma N Engl J Med 136 22-26
[7]  
Lacy M(2020)CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma Blood 136 25-3134
[8]  
Lipe B(2020)Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes Blood 134 3134-26
[9]  
Little RF(2019)Open-label pilot study of genetically engineered NY-ESO-1 specific T cells (GSK3377794) alone or in combination with pembrolizumab in relapsed and refractory multiple myeloma Blood 136 25-930
[10]  
Nikonova A(2020)Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform fast CAR-T cell therapy for patients with relapsed/refractory multiple myeloma Blood 134 930-25
12345678910